Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sakar Healthcare Ltd ( (IN:SAKAR) ) has shared an announcement.
Sakar Healthcare Ltd announced that its oncology manufacturing site has been approved as a production source for Accord Healthcare UK’s Imatinib Accord 100 mg and 400 mg film-coated tablets for the European Union market, following an EU variation approval by the European Medicines Agency. This marks the first of nine oncology products that Accord plans to transfer to Sakar, positioning the Indian company as a key supplier for Accord’s European oncology portfolio, and is expected to boost Sakar’s top-line sales and improve capacity utilisation while enabling it to prepare for supplying a broader range of approved products overseas.
More about Sakar Healthcare Ltd
Sakar Healthcare Ltd is an India-based pharmaceutical manufacturer with a dedicated oncology facility near Ahmedabad, producing oncology formulations for regulated markets. The company focuses on supplying finished dosage products to international partners and expanding its presence in overseas markets, particularly in Europe.
Average Trading Volume: 30,018
Technical Sentiment Signal: Buy
Current Market Cap: 9.11B INR
For a thorough assessment of SAKAR stock, go to TipRanks’ Stock Analysis page.